Navigation Links
'Autoinjector' Offers Safe, Speedy Care for Life-Threatening Seizures: Study
Date:2/15/2012

WEDNESDAY, Feb. 15 (HealthDay News) -- Using an autoinjector device to deliver anti-seizure drugs into muscle is a fast, safe and effective way to treat status epilepticus, a prolonged type of seizure that lasts longer than five minutes, researchers report.

"This is a very important study for persons with epilepsy," said one outside expert, Dr. Jacqueline French, first vice president of the American Epilepsy Society. "Prolonged seizures and status epilepticus can lead to brain damage, prolonged hospitalization, and other serious harm. The earlier treatment is initiated, the greater the likelihood that the seizure activity can be aborted quickly, and harm can be avoided," she said.

French, who is also professor of neurology at the Comprehensive Epilepsy Center at New York University Langone Medical Center, New York City, believes the study "will set a new standard for treatment by emergency teams, that will lead to substantial benefit for persons with epilepsy."

The study, funded by the U.S. National Institute of Neurological Disorders and Stroke (NINDS), appears in the Feb. 16 issue of the New England Journal of Medicine.

Status epilepticus is a serious, potentially life-threatening medical emergency that causes 55,000 deaths each year in the United States. First-line treatment typically involves intravenous (IV) delivery of anti-seizure drugs. However, starting an IV in a patient having a seizure can be challenging for paramedics and takes up precious time.

This study, carried out by paramedics, examined whether using an autoinjector to deliver an anti-seizure drug directly into a patient's thigh muscle is as safe and effective as using an IV. The researchers compared how well each method stopped patients' seizures by the time the ambulance arrived at the emergency department.

Two different seizure-fighting medicines -- midazolam and lorazepam -- were used in the study. Both are benzodiazepines and are known to be effective in controlling seizures. Midazolam was used in the autoinjectors because it is rapidly absorbed from muscle.

The researchers say that 73 percent of patients who received midazolam through an autoinjector were seizure-free when they arrived at the emergency department, compared with 63 percent of those who received IV treatment with lorazepam.

Patients in the autoinjector/midazolam group were also less likely to require hospitalization than those in the IV/lorazepam group. Both groups had similarly low rates of recurrent seizures.

"Patients with status epilepticus can suffer severe consequences if seizures are not stopped quickly. This study establishes that rapid intramuscular injection of an anticonvulsant drug is safe and effective," Dr. Walter Koroshetz, NINDS deputy director, said in an institute news release.

Another expert agreed.

"This study represents a major step toward keeping epilepsy patients safer from the serious neurologic and medical risks of prolonged status epilepticus," said Dr. Cynthia Harden, chief of the Division of Epilepsy and Electroencephalography at the Cushing Neuroscience Institute, part of the North Shore-LIJ Health System in Manhasset, N.Y.

Could the autoinjector be safely used by non-medical personnel, such as family or friends? Harden said only more research can tell. "The device has great value in the clinical setting, when used by paramedics," she said, "and the safety of its use by non-medical persons such as family members remains to be clarified."

The study authors agreed. Currently, they said, the use of midazolam requires on-site medical supervision, and further research is needed before autoinjectors with the drug might be available for use by epilepsy patients and their family members.

More information

The Epilepsy Foundation has more about status epilepticus.

-- Robert Preidt

SOURCES: Cynthia L. Harden, M.D., Chief, Division of Epilepsy and Electroencephalography at the Cushing Neuroscience Institute, part of the North Shore-LIJ Health System in Manhasset, N.Y.; Jacqueline A. French, M.D., professor, neurology, and director of translational research and clinical trials, Comprehensive Epilepsy Center, New York University Langone Medical Center, New York City, and first vice president, American Epilepsy Society; U.S. National Institute of Neurological Disorders and Stroke, news release, Feb. 15, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. UH Case Medical Center offers new therapy for gynecologic cancer patients
2. New test offers greater accuracy in early detection of colorectal cancer
3. University of Kentucky offers stroke stem cell trial
4. Study Offers Clues to Why Some Dont Benefit From Asthma Drugs
5. Proposed standard offers best practices to help ensure pharmaceutical supply chain integrity
6. Contralateral prophylactic mastectomy offers limited gains for breast cancer patients
7. Public health insurance offers insured infants better, less costly care than private plans
8. Echocardiography offers the future for infarct size quantification
9. Lancet pneumonia study offers new hope for reducing No. 1 cause of child death
10. Cavemen Knew It: Cooked Meat Offers More Energy
11. In a childhood cancer, basic biology offers clues to better treatments
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Autoinjector' Offers Safe, Speedy Care for Life-Threatening Seizures: Study
(Date:2/27/2017)... ... February 27, 2017 , ... This ... laser diffraction analysis as a tool to characterize particle size distributions in the ... obtain improved results and novel scientific findings. It describes methods of optimized and ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair ... announce a new informational post on robotic hair transplantation. San Francisco residents may ... transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment can be ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der ... , ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements for ...
(Date:2/26/2017)... ... 2017 , ... ODH, Inc.™ announced today it will exhibit and speak ... City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will ... Medicaid population health management. , ODH will also have an exhibit booth where attendees ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... promotions on tooth replacement options at his office, Antoine Dental Center. Currently, patients ... for $18,499. Some restrictions may apply, but patients can learn more about these ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... at the Cowen and Company 37 th Annual ... on Tuesday, March 7, 2017 at 11:20 a.m. Eastern ... presentation can be accessed at http://wsw.com/webcast/cowen38/zbh .  The ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:2/24/2017)... 24, 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies ... eye market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Dry eye ...
(Date:2/24/2017)... Feb. 24, 2017 Medical information groups ... increase their self-service capabilities to manage inquiries from ... New research from consulting leader Best ... developed self-service website portals where HCPs can sign ... one of many findings to emerge from the ...
Breaking Medicine Technology: